ImageneBio (IMA) Stock Price, News & Analysis

Company Overview

ImageneBio, Inc. is a biotechnology company focused on advancing precision oncology through blood-based molecular testing and data analysis. The company develops technologies designed to help identify and monitor cancer-related genomic signals using liquid biopsy samples.

Its platform is intended to support the detection and tracking of tumor biomarkers, potentially helping clinicians assess treatment response, identify disease progression, and guide more personalized cancer-care decisions. ImageneBio combines molecular analysis with computational tools to translate circulating biological information into insights for oncology research and clinical use.

The company’s offerings are directed primarily toward cancer patients, healthcare providers, pharmaceutical companies, and research organizations involved in drug development and precision medicine. Publicly available information about ImageneBio’s historical development, geographic operations, and leadership is limited.

Key Stats

• Today's Range: $4.02 to $4.45
• 50-Day Range: $4.00 to $5.69
• 52-Week Range: $3.88 to $9.10
• Volume: 15,560 shs
• Average Volume: 119,898 shs
• Market Capitalization: $47.45 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $28.00
• Consensus Rating: Reduce

ImageneBio Stock Analysis - MarketRank™

ImageneBio scored higher than 33% of companies evaluated by MarketBeat, and ranked 709th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Reduce

Consensus Rating

ImageneBio has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 2 sell ratings.

Upside Potential

ImageneBio has a consensus price target of $28.00, representing about 585.4% upside from its current price of $4.09.

Amount of Analyst Coverage

ImageneBio has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for ImageneBio are expected to decrease in the coming year, from ($3.23) to ($3.64) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ImageneBio is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ImageneBio is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.55% of the float of ImageneBio has been sold short.

Short Interest Ratio / Days to Cover

ImageneBio has a short interest ratio ("days to cover") of 4.19.

Change versus previous month

Short interest in ImageneBio has recently increased by 86.74%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ImageneBio does not currently pay a dividend.

Dividend Growth

ImageneBio does not have a long track record of dividend growth.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: 0.50

News Sentiment

ImageneBio has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for ImageneBio this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for IMA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ImageneBio insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.22% of the stock of ImageneBio is held by insiders.

Percentage Held by Institutions

75.00% of the stock of ImageneBio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 10/28/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:IMA
• Previous Symbol: NASDAQ:IMA
• CIK: 1835579
• Web: www.imagenebio.com
• Phone: (857) 343-8292
• Fax: N/A
• Employees: 18
• Year Founded: 2016

Price Target and Rating

• Average Price Target for ImageneBio: $28.00
• High Price Target: $28.00
• Low Price Target: $28.00
• Potential Upside/Downside: +569.9%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.58)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$45.35 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -38.99%
• Return on Assets: -34.84%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 21.47
• Quick Ratio: 21.47

Sales & Book Value

• Annual Sales: $800 thousand
• Price / Sales: 59.31
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $11.91 per share
• Price / Book: 0.35

Miscellaneous

• Outstanding Shares: 11,351,000
• Free Float: 11,099,000
• Market Cap: $47.45 million
• Optionable: Not Optionable
• Beta: 0.74